BB Biotech AG (BB Biotech AG) Debt-to-Equity : 0.13 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is BB Biotech AG Debt-to-Equity?

BB Biotech AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. BB Biotech AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $352.57 Mil. BB Biotech AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $2,686.42 Mil. BB Biotech AG's debt to equity for the quarter that ended in Dec. 2023 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BB Biotech AG's Debt-to-Equity or its related term are showing as below:

BBAGF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.05 Max: 0.14
Current: 0.13

During the past 13 years, the highest Debt-to-Equity Ratio of BB Biotech AG was 0.14. The lowest was 0.01. And the median was 0.05.

BBAGF's Debt-to-Equity is ranked better than
52.43% of 1072 companies
in the Biotechnology industry
Industry Median: 0.145 vs BBAGF: 0.13

BB Biotech AG Debt-to-Equity Historical Data

The historical data trend for BB Biotech AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Debt-to-Equity Chart

BB Biotech AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.02

0.11

0.14

0.13

BB Biotech AG Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Dec17	Dec18	Dec19	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.14	0.14	0.14	0.14	0.13

Competitive Comparison of BB Biotech AG's Debt-to-Equity

For the Biotechnology subindustry, BB Biotech AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BB Biotech AG's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Debt-to-Equity falls into.

BB Biotech AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BB Biotech AG's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	352.567)	/	2686.421
	=	0.13

BB Biotech AG's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	352.567)	/	2686.421
	=	0.13

BB Biotech AG (GREY:BBAGF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BB Biotech AG Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BB Biotech AG (BB Biotech AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (GREY:BBAGF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BIONz:UK BBZA:Germany BION:Switzerland

Address

Schwertstrasse 6, Schaffhausen, CHE, CH-8200

Website

https://www.bbbiotech.com

BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (BB Biotech AG) Headlines

No Headlines